Literature DB >> 20479204

Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.

Eva Poveda1, Lourdes Anta, José Luis Blanco, José Luis Casado, Félix Gutiérrez, Federico García, Juan Luis Gómez-Sirvent, José Antonio Iribarren, Vincent Soriano, Carmen de Mendoza.   

Abstract

The presence of resistance mutations in patients failing tipranavir or darunavir was examined at the national drug resistance database of the Spanish AIDS Research Network. Although mutations emerging during tipranavir and darunavir failures differed considerably, cross-resistance was found in up to half of the patients tested. Interestingly, mutation 54L, which is associated with tipranavir hypersusceptibility, was selected in half of the darunavir failures. Thus, resistance testing seems mandatory to ensure the benefit of the sequential use of these drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479204      PMCID: PMC2897318          DOI: 10.1128/AAC.00160-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.

Authors:  Constance Delaugerre; Juliette Pavie; Pierre Palmer; Jade Ghosn; Stephane Blanche; Laurent Roudiere; Stephanie Dominguez; Emmanuel Mortier; Jean-Michel Molina; Pierre de Truchis
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

Review 2.  Update of the drug resistance mutations in HIV-1: December 2009.

Authors:  Victoria A Johnson; Francoise Brun-Vezinet; Bonaventura Clotet; Huldrych F Gunthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Journal:  Top HIV Med       Date:  2009-12

3.  Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.

Authors:  Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlama; Bonaventura Clotet; Adriano Lazzarin; Margaret A Johnson; Dietmar Neubacher; Douglas Mayers; Hernan Valdez
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

4.  Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

Authors:  John D Baxter; Jonathan M Schapiro; Charles A B Boucher; Veronika M Kohlbrenner; David B Hall; Joseph R Scherer; Douglas L Mayers
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

Review 5.  Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Authors:  Eric Lefebvre; Celia A Schiffer
Journal:  AIDS Rev       Date:  2008 Jul-Sep       Impact factor: 2.500

6.  Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.

Authors:  Vincenzo Spagnuolo; Nicola Gianotti; Elena Seminari; Laura Galli; Giuliana Fusetti; Stefania Salpietro; Adriano Lazzarin; Antonella Castagna
Journal:  J Acquir Immune Defic Syndr       Date:  2009-02-01       Impact factor: 3.731

7.  Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

Authors:  Eva Poveda; Carmen de Mendoza; Luz Martin-Carbonero; Angélica Corral; Verónica Briz; Juan González-Lahoz; Vincent Soriano
Journal:  J Antimicrob Chemother       Date:  2007-07-23       Impact factor: 5.790

8.  Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.

Authors:  Carmen de Mendoza; Judit Morelló; Pilar Garcia-Gascó; Sonia Rodríguez-Novoa; Vincent Soriano
Journal:  Expert Opin Pharmacother       Date:  2007-04       Impact factor: 3.889

9.  Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Authors:  Bonaventura Clotet; Nicholas Bellos; Jean-Michel Molina; David Cooper; Jean-Christophe Goffard; Adriano Lazzarin; Andrej Wöhrmann; Christine Katlama; Timothy Wilkin; Richard Haubrich; Calvin Cohen; Charles Farthing; Dushyantha Jayaweera; Martin Markowitz; Peter Ruane; Sabrina Spinosa-Guzman; Eric Lefebvre
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321

  9 in total
  6 in total

1.  Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.

Authors:  Manabu Aoki; Matthew L Danish; Hiromi Aoki-Ogata; Masayuki Amano; Kazuhiko Ide; Debananda Das; Yasuhiro Koh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

Review 2.  Darunavir: a review of its use in the management of HIV-1 infection.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2014-01       Impact factor: 11.431

Review 3.  Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2018-07       Impact factor: 11.431

4.  HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.

Authors:  Kate El Bouzidi; Ellen White; Jean L Mbisa; Caroline A Sabin; Andrew N Phillips; Nicola Mackie; Anton L Pozniak; Anna Tostevin; Deenan Pillay; David T Dunn
Journal:  J Antimicrob Chemother       Date:  2016-09-28       Impact factor: 5.790

Review 5.  AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities.

Authors:  Vicente Soriano; José M Ramos; Pablo Barreiro; Jose V Fernandez-Montero
Journal:  Viruses       Date:  2018-05-30       Impact factor: 5.048

6.  Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.

Authors:  Gilberto Betancor; César Garriga; Maria C Puertas; María Nevot; Lourdes Anta; José L Blanco; M Jesús Pérez-Elías; Carmen de Mendoza; Miguel A Martínez; Javier Martinez-Picado; Luis Menéndez-Arias; José Antonio Iribarren; Estrella Caballero; Esteban Ribera; Josep Maria Llibre; Bonaventura Clotet; Angels Jaén; David Dalmau; José María Gatel; Joaquín Peraire; Francesc Vidal; Carmen Vidal; Melchor Riera; Juan Córdoba; José López Aldeguer; María José Galindo; Félix Gutiérrez; Marta Álvarez; Federico García; Pilar Pérez-Romero; Pompeyo Viciana; Manuel Leal; José Carlos Palomares; Juan Antonio Pineda; Isabel Viciana; Jesús Santos; Patricia Rodríguez; Juan Luis Gómez Sirvent; Carolina Gutiérrez; Santiago Moreno; Mayte Pérez-Olmeda; José Alcamí; Carmen Rodríguez; Jorge del Romero; Angelina Cañizares; José Pedreira; Celia Miralles; Antonio Ocampo; Luis Morano; Antonio Aguilera; Carolina Garrido; Gustavo Manuzza; Eva Poveda; Vicente Soriano
Journal:  Retrovirology       Date:  2012-08-13       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.